{
    "clinical_study": {
        "@rank": "14853", 
        "arm_group": {
            "arm_group_label": "1", 
            "arm_group_type": "Experimental", 
            "description": "Combined Modality Treatment of Radiation therapy, 5-Fluorouracil, Oxaliplatin and Lapatinib followed by Surgery"
        }, 
        "brief_summary": {
            "textblock": "With improvements in response rate and survival seen for HER2 positive patients treated with\n      HER2 blockade in the metastatic setting, the use of HER2 blockade in the neoadjuvant setting\n      to increase antitumor effect shows promise.  Patients with previously untreated localized\n      HER2 positive esophageal, GE junction and gastric adenocarcinomas will be enrolled.\n      Patients meeting all inclusion/exclusion criteria will receive neoadjuvant treatment with\n      concurrent chemotherapy and radiation therapy beginning on day 1 of treatment. During the\n      lead-in safety portion, the optimal dose of lapatinib will be determined."
        }, 
        "brief_title": "Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "HER2 Positive Esophagogastric Cancer", 
        "condition_browse": {
            "mesh_term": "Adenocarcinoma"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, non-randomized, Phase II study with a lead-in safety cohort.  The\n      study will evaluate the combination of 5-Fluorouracil, Oxaliplatin and Lapatinib with\n      radiation therapy as neoadjuvant treatment for patients with previously untreated  localized\n      HER2 positive esophagogastric adenocarcinomas.   Approximately 12 patients will be enrolled\n      in the lead-in cohort to evaluate the safety of the combination. Following the lead-in\n      cohort, Phase II will commence and up to 30 additional patients may be treated. The starting\n      doses will be administered as follows:\n\n      5-FU 225 mg/mg2 continuous intravenous (IV) infusion Days 1 - 42 during XRT;\n\n      Oxaliplatin 85 mg/m2 Days 1, 15 and 29, given by IV infusion, per institutional standard;\n\n      Lapatinib Continuous PO daily dosing during XRT (final dose determined during lead-in\n      cohort)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed Stage I, II, or III adenocarcinoma of the esophagus (lower\n             \u2153), GE junction, or gastric cardia.\n\n          -  Clinical stage I, II, or III as assessed by required baseline staging. In addition,\n             patients with celiac node involvement (stage IVa) are eligible.\n\n          -  Patients must be surgical candidates based on stage and location of disease as well\n             as other medical conditions and risk factors.\n\n          -  Positive HER2 status (overexpression and/or amplification of HER2 in primary tumor)\n             as defined by FISH (HER2 FISH positivity).\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.\n\n          -  Patient must be able to swallow and absorb oral medication.\n\n          -  Patients must have an indwelling central venous access catheter.\n\n          -  Adequate hematologic, renal, and hepatic  function:\n\n          -  Known brain or leptomeningeal metastases.\n\n          -  Male patients willing to use adequate contraceptive measures.\n\n          -  Female patients who are not of child-bearing potential, and female patients of\n             child-bearing potential who agree to use adequate contraceptive measures, who are not\n             breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours\n             prior to start of treatment.\n\n          -  Life expectancy \u2265 12 weeks.\n\n          -  Age \u226518 years of age.\n\n          -  Willingness and ability to comply with trial and follow-up procedures.\n\n          -  Ability to understand the nature of this trial and give written informed consent.\n\n        Exclusion Criteria:\n\n          -  Patients with evidence of distant metastases are ineligible, as are patients who are\n             not potential surgical candidates based on location or extent of local disease.\n             Patients with celiac nodal disease (Stage IVa) will be allowed on study.\n\n          -  Previous anti-cancer treatment for esophageal, GE junction, or gastric cancer.\n\n          -  Any other investigational agents within the 28 days prior to day 1 of the study.\n\n          -  Known active hepatic or biliary disease (with exception of patients with Gilbert's\n             syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease\n             per investigator assessment).\n\n          -  Concurrent treatment with drugs known to be strong inhibitors or inducers of\n             isoenzyme CYP3A that cannot be discontinued or switched to different medication prior\n             to starting study drug.\n\n          -  Concurrent use of St. John's wort and grapefruit /grapefruit juice \u22647 days prior to\n             starting study drug is not allowed.\n\n          -  Ongoing treatment with full-dose warfarin or its equivalent. Prophylactic treatment\n             with 1 mg daily of warfarin and/or low molecular weight heparin is allowed.\n\n          -  History of any other disease, physical examination finding, or clinical laboratory\n             finding giving reasonable suspicion of a disease or condition that contraindicates\n             the use of a novel regimen, or that might affect interpretation of the results of\n             this study or render the subject at high-risk for treatment complications.\n\n          -  Active gastrointestinal (GI) disease or other condition that in the opinion of the\n             investigator will interfere significantly with the absorption, distribution,\n             metabolism, or excretion of oral therapy (e.g. ulcerative disease, uncontrolled\n             nausea, or vomiting).\n\n          -  Poorly controlled or clinically significant atherosclerotic vascular disease\n\n          -  A serious active infection at the time of treatment, or another serious underlying\n             medical condition that would impair the ability of the patient to receive protocol\n             treatment.\n\n          -  Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis\n             C (HCV).\n\n          -  Presence of other active cancers, or history of treatment for invasive cancer \u22645\n             years. Patients with stage I cancer who have received definitive local treatment at\n             least 3 years previously, and are considered unlikely to recur are eligible. All\n             patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible,\n             as are patients with history of non-melanoma skin cancer.\n\n          -  Psychological, familial, sociological, or geographical conditions that do not permit\n             compliance with the protocol.\n\n          -  Inability or unwillingness to comply with study and/or follow-up procedures outlined\n             in the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01769508", 
            "org_study_id": "SCRI GI 166"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "5-FU, 225 mg/m2 IVCI, during XRT.", 
                "intervention_name": "5-Fluorouracil", 
                "intervention_type": "Drug", 
                "other_name": "Combined Modality Treatment"
            }, 
            {
                "arm_group_label": "1", 
                "description": "Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug", 
                "other_name": "Combined Modality Treatment"
            }, 
            {
                "arm_group_label": "1", 
                "description": "Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion", 
                "intervention_name": "Lapatinib", 
                "intervention_type": "Drug", 
                "other_name": "Combined Modality Treatment"
            }, 
            {
                "arm_group_label": "1", 
                "description": "Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6", 
                "intervention_name": "Radiation Therapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Oxaliplatin", 
                "Lapatinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Esophagogastric Adenocarcinoma", 
            "5-Fluorouracil", 
            "Oxaliplatin", 
            "Lapatinib", 
            "Radiation Therapy", 
            "Surgery"
        ], 
        "lastchanged_date": "January 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33916"
                    }, 
                    "name": "Florida Cancer Specialists - South"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32804"
                    }, 
                    "name": "Florida Hospital Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pensacola", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32503"
                    }, 
                    "name": "Woodlands Medical Specialists"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33705"
                    }, 
                    "name": "Florida Cancer Specialists-North"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30501"
                    }, 
                    "name": "Northeast Georgia Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grand Rapids", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49503"
                    }, 
                    "name": "Grand Rapids Oncology Program"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }, 
                    "name": "Oncology Hematology Care"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37404"
                    }, 
                    "name": "Chattanooga Oncology and Hematology Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study With Lead-in Safety Cohort of 5-Fluorouracil, Oxaliplatin and Lapatinib in Combination With Radiation Therapy as Neoadjuvant Treatment for Patients With Localized HER2 Positive Esophagogastric Adenocarcinomas", 
        "overall_contact": {
            "email": "asksarah@scresearch.net", 
            "last_name": "Sarah Cannon Research Institute", 
            "phone": "1-877-691-7274"
        }, 
        "overall_official": {
            "affiliation": "SCRI Development Innovations, LLC", 
            "last_name": "Johanna C Bendell, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "This trial seeks to evaluate the pathological complete response (pCR) rate of the combination of lapatinib and chemoradiation as neoadjuvant treatment for patients with localized HER2 positive esophagogastric adenocarcinomas.", 
                "measure": "Pathologic Complete Response Rate (pCR rate)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "An additional primary objective is to evaluate the safety and optimal dose of lapatinib when added to 5-FU, oxaliplatin and radiation therapy.", 
                "measure": "Safety and optimal dose of regimen", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01769508"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression Free Survival will be evaluated for neoadjuvant patients treated with 5-FU, oxaliplatin, lapatinib and radiation therapy.", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "The toxicity assessments will be performed at week 4, once during week 8-10 and at the end of the study.", 
                "measure": "Toxicity profile for neoadjuvant patients treated with 5-FU, Oxaliplatin, Lapatinib and radiation therapy", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Time to Progression will be evaluated for neoadjuvant patients treated with 5-FU, oxaliplatin, lapatinib and radiation therapy.", 
                "measure": "Time to Progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Overall Survival will be evaluated for neoadjuvant patients treated with 5-FU, oxaliplatin, lapatinib and radiation therapy.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "source": "SCRI Development Innovations, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "SCRI Development Innovations, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}